PK/PD Study of GW823093 in Japanese Subjects With T2DM: A Single-blind, Placebo Controlled, Randomized, Multi-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GW823093C Administered Orally for 7 Days in Japanese Subjects With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Denagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 14 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 23 Oct 2006 New trial record.